Abstracts A143 multiple sclerosis heading term or by using quality of life and multiple sclerosis as separate MeSH terms. Urinary bladder was entered as a heading term, and all associated subheadings were included in the search box. Studies were included if a HRQOL instrument measuring bladder function or urinary incontinence was administered to a sample of MS patients. References in these articles were searched for additional studies that met inclusion criteria. RESULTS: Six articles initially met inclusion criteria. An additional 2 articles were found from their references. A total of 8 different instruments were used ranging from 6 to 30 items and tested across 3 to 10 different domains. Articles varied in terms of sample size (30 to 9,688 participants), study design (cross-sectional vs. prospective cohort), and objectives (HRQOL impact vs. instrument validation). Six disease-specific HRQOL instruments were originally designed for use in other populations, and 3 were gender specific. Moderate to severe bladder dysfunction in patients with MS was prevalent in 49% to 79% of the study samples and the urinary symptoms negatively impacted HRQOL in all the studies. CONCLUSIONS: The use of HRQOL instruments specific to bladder dysfunction in patients with MS is limited. Study design variability made it difficult to assess overall impact of bladder symptoms on HRQOL. Further validation of existing instruments that include both sexes and whose bladder dysfunction is of neurogenic origin is needed. OBJECTIVES: Medications are critical for preventing and controlling migraine headaches. The objectives of this project are to describe anti-migraine drug (AMD) utilization, price and reimbursement trends, and to compare market share competitions between Ergots and serotonin 5-HT1 receptor agonists (triptans). METHODS: Study drugs included ergot derivatives and triptans. A retrospective, descriptive time-series analysis was conducted for this study. The data source is the national Medicaid pharmacy claim database from CMS. The quarterly prescription numbers and reimbursement amounts were calculated from 1st quarter 1991 to 4th quarter 2008. The
PND30 NATALIZUMAB TREATMENT IS ASSOCIATED WITH AN IMPROVEMENT IN PATIENT-REPORTED FATIGUE AND COGNITIVE FUNCTION OVER TIME
Stephenson JJ 1 , Hou L 1 , Agarwal SS 2 , Rajagopalan K 2 , Kamat SA 1 1 HealthCore, Inc., Wilmington, DE, USA, 2 Biogen Idec, Wellesley, MA, USA OBJECTIVES: To evaluate changes in patient-reported fatigue and cognitive function after one year of natalizumab treatment in MS patients. METHODS: The study population consists of MS patients initiating natalizumab treatment who agreed to participate in a 12-month longitudinal study. The study assessed patient experiences with natalizumab using validated patient-reported outcome (PRO) measures prior to treatment initiation and after 3 rd , 6 th and 12 th infusions. The current analysis reports change in fatigue and cognitive functioning from baseline through the 12 th natalizumab infusion. Fatigue is measured by the 5-question Modified Fatigue Impact Scale-5 (MFIS-5, score range 0-20) with lower scores indicating lower impact of fatigue on physical, cognitive, and psychosocial functioning; cognitive function is measured by the 6-question Medical Outcomes Study Cognitive Functioning Scale (MOS-Cog Scale, score range 6-36) with higher scores indicating better reasoning skills, memory, concentration, ability to start several actions at one time and ability to react to what is said or done. Regression analysis was used to control for baseline (BL) covariates such as age, years since MS diagnosis, number of natalizumab infusions received, MS level of disability and functional status, number of MS drugs used prior to natalizumab and comorbidity burden. RESULTS: Results from this on-going study are presented for 192 patients completing the BL through 12 th infusion follow-up surveys. The mean number of years since MS diagnosis was 10.16 (SD = 8.23). Most patients were female (78%) and the mean age was 46.09 (SD = 10.78). On average, MFIS scores decreased significantly (BL 12.23 ± 2.2; 12 th infusion score 10.97 ± 2.2, p < 0.001) and MOS-Cog scores increased significantly over time (BL 25.8 ± 1.4; 12 th infusion score 26.91 ± 1.4, p < 0.001) after controlling for covariates. CONCLUSIONS: MS patients reported improvements in the impact of fatigue and overall cognitive function after one year of natalizumab treatment.
PND31 IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS RECEIVING NATALIZUMAB IN THE UNITED STATES
Hou L 1 , Stephenson JJ 1 , Agarwal SS 2 , Rajagopalan K 2 , Kamat SA 1 1 HealthCore, Inc., Wilmington, DE, USA, 2 Biogen Idec, Wellesley, MA, USA OBJECTIVES: To assess the change in general health-related quality of life (HRQoL) of multiple sclerosis (MS) patients after one year of natalizumab treatment. METHODS: MS patients, newly starting natalizumab, were recruited to participate in a longitudinal observational study to assess general health-related quality of life using the SF-12v2 prior to natalizumab initiation and after the 3 rd , 6 th and 12 th infusions. Higher physical component summary scores (PCS) and mental component summary scores (MCS) on the SF-12v2 indicate better HRQoL. Statistical regression models were used to evaluate changes in PCS and MCS scores from baseline through the 12 th infusion after controlling for baseline patient-level and treatment characteristics. RESULTS: Data for 192 patients who had completed the baseline through 12 th infusion assessments of this ongoing study are reported. The mean age was 46.09 (SD = 10.78) and the majority of patients were female (78%). The mean number of years since MS diagnosis was 10.16 (SD = 8.23). The PCS score improved significantly from baseline (BL 33.30 ± 7.12, 12 th infusion 35.91 ± 7.12; p < 0.001); similar improvements were observed in the MCS scores which also improved significantly from baseline (BL 43.12 ± 1.53, 12 th infusion 47.95 ± 1.53; p < 0.001). CONCLUSIONS: Patients reported improvements in general HRQoL measures after one year of natalizumab treatment in the usual care setting. These results are consistent with results from pivotal clinical trials and document the beneficial impact of natalizumab on HRQoL of MS patients.
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ANALYSIS OF DULOXETINE UTILIZATION AMONG COMMERCIALLY-INSURED FIBROMYALGIA PATIENTS
Chen SY 1 , Wu N 1 , Boulanger L 1 , Rao P 2 , Peng X 3 , Zhao Y 3 1 Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2 Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA, 3 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: To assess duloxetine utilization among commercially-insured fibromyalgia patients. METHODS: This study analyzed administrative claims for fibromyalgia patients aged 18-64 who initiated duloxetine in 2006. Initiation was defined as no duloxetine coverage in the prior 90 days, with the first duloxetine prescription dispense date as the "index date." Patients were excluded if they had less than 30 duloxetine supply days in the 12-month post-index period, or diagnosis of diabetic peripheral neuropathic pain or depression in the 12 months pre-index period. All duloxetine patients were classified in five cohorts based on index dosage: <30 mg, 30 mg, 31-59 mg, 60 mg, and >60 mg. Changes in dosage, average daily dosage (ADD), and adherence to duloxetine (medication possession ratio ≥0.8 as high adherence) were compared across cohorts. Multivariate regression models were performed to examine the association between index dosage and health care costs, controlling for demographics and clinical characteristics. RESULTS: Of 4,869 fibromyalgia patients identified, 4.4% had an index dosage of <30 mg, 22.4% of 30 mg, 5.9% of 31-59 mg, 60.4% of 60 mg, and 7.0% of >60 mg. 28% of total patients experienced any increase in dosage, while 15.9% experienced any decrease. Among those with any dosage change (n = 1,651), patients with an index dosage of 31-59 mg had the shortest duration before any dosage change (89 days), followed by those in the <30 mg, >60 mg, 30 mg, and 60 mg (95, 100, 104, and 139 days, respectively) cohorts. ADD increased with index dosage. Patients with <60 mg index dosage were less likely to be adherent than those in the 60 mg cohort (odds ratios ranged 0.61 to 0.78, all p < 0.05). Patients in the >60 mg cohort had higher total health care costs compared with those in the 60 mg cohort (adjusted difference: $3,747, p < 0.05). CONCLUSIONS: About one-third of duloxetine treated fibromyalgia patients experienced any dosage change. Duloxetine adherence and ADD, and health care costs differ by duloxetine index dosage.
PND33
PREDICTORS OF PAIN MEDICATION SELECTION AMONG PATIENTS DIAGNOSED WITH FIBROMYALGIA
Zhao Y 1 , Chen SY 2 , Boulanger L 2 , Nagar S 2 , Fraser K 2 , Wu N 2 1 Eli Lilly and Company, Indianapolis, IN, USA, 2 Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA OBJECTIVES: Multiple pharmacologic therapies have been recommended for managing fibromyalgia. However, the factors associated with each treatment initiation have not been well established. This study assessed demographic and clinical predictors of duloxetine versus other pain medications dispensed among patients with fibromyalgia. METHODS: Employing a retrospective cohort design and data from commercial insurance, this study examined predictors of treatment among fibromyalgia patients who were 18 to 64 years old and initiated duloxetine versus selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), venlafaxine, gabapentin, pregabalin, tramadol or non-tramadol narcotics between January 1, 2007 and December 31, 2008. Treatment initiation was defined as no access to the same medication over the previous 90 days, and the most recent initiation date was set as the index date. All patients selected had at least 1 fibromyalgia diagnosis (ICD-9-CM: 729.1) in the 12 months prior to initiation of each study therapy. Multiple logistic regression models were estimated to assess predictors of initiating duloxetine versus each of the other fibromyalgia therapies. RESULTS: Commercially insured fibromyalgia patients (n = 117,305) were on average 48 years of age, and 76% were females. Common fibromyalgia-related comorbidities were low back pain (35%), osteoarthritis (17%), and diabetes (12%). After controlling for demographic and clinical characteristics, those 35+ years of age, females, and patients who received SSRIs, TCAs, venlafaxine, gabapentin, or pregabalin over the 1-year pre-index period were generally more likely to initiate duloxetine than the other study medications. Other predictors of duloxetine initiation included higher prescription copayment and history of rheumatoid arthritis, osteoporosis, and sleep disturbance. CONCLUSIONS: These findings indicate that age, cost sharing, presence of selected comorbidities, and prior use of certain medications to treat pain were significant predictors of duloxetine initiation among working age, commercially insured fibromyalgia patients.
